Among the 44 DLBCL anti-PD-1 treated patients, the best ORR was 34.1%; thirteen patients (29.5%) had a complete response, one patient (2.3%) had a partial response, and one patient (2.3%) had a stable disease. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.